Day One Biopharmaceuticals Announces FDA approved of New Drug Application for relapsed or refractory pediatric low-grade glioma (pLGG)
Yesterday Day One Biopharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved their New Drug Application (NDA)...